Adamantinous craniopharyngioma
Therapeutic area
Neurology
Rare disease
No
- Definition
- A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Adamantinous craniopharyngioma
- Therapeutic area
- Neurology
- adamantinous craniopharyngioma
- adamantinomatous craniopharyngioma
- adamantinous Rathke's pouch neoplasm
- adamantinous Rathke's pouch tumor
- adamantinous Rathke's pouch tumour
- adamantinous craniopharyngioma (morphologic abnormality)
- adamantinous neoplasm of Rathke's pouch
- adamantinous tumor of Rathke's pouch
- adamantinous tumour of Rathke's pouch
- craniopharyngioma, adamantinomatous
- Severity
- Severe
- Neurology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0002787
- Parent condition
- MONDO:0018907
Related records
Broader conditions (34)
- Benign connective and soft tissue neoplasm
- Benign epithelial neoplasm
- Benign neoplasm
- Bone benign neoplasm
- Bone disorder
- Bone neoplasm
- Cancer or benign tumor
- Central nervous system disorder
- Central nervous system neoplasm
- Central nervous system organ benign neoplasm
- Connective and soft tissue neoplasm
- Connective tissue disorder
- Connective tissue neoplasm
- Craniopharyngioma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disorder of facial skeleton
- Epithelial neoplasm
- Head and neck neoplasm
Trials (4)
- ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
- FOG-001 in Locally Advanced or Metastatic Solid Tumors
- MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
- Tocilizumab in Children With ACP